Curofy
Maintenance Rx for mCRPC delays progression after docetaxel
For patients with metastatic castration-resistant prostate cancer (mCRPC) starting a maintenance program, a novel androgen-receptor pathway inhibitor given directly after docetaxel and before progression appears to extend event-free survival (EFS).
See this content immediately after install